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Abstract
Background: Monoclonal antibodies are promising anti-
myeloma treatments. As immunoglobulins, monoclonal 
antibodies have the potential to be identified by serum 
protein electrophoresis (SPE) and immunofixation elec-
trophoresis (IFE). Therapeutic antibody interference with 
standard clinical SPE and IFE can confound the use of 
these tests for response assessment in clinical trials and 
disease monitoring.
Methods: To discriminate between endogenous myeloma 
protein and daratumumab, a daratumumab-specific 
immunofixation electrophoresis reflex assay (DIRA) was 
developed using a mouse anti-daratumumab antibody. To 
evaluate whether anti-daratumumab bound to and shifted 
the migration pattern of daratumumab, it was spiked into 
daratumumab-containing serum and resolved by IFE/SPE. 
The presence (DIRA positive) or absence (DIRA negative) 
of residual M-protein in daratumumab-treated patient 
samples was evaluated using predetermined assessment 
criteria. DIRA was evaluated for specificity, limit of sensi-
tivity, and reproducibility.
Results: In all of the tested samples, DIRA distinguished 
between daratumumab and residual M-protein in com-
mercial serum samples spiked with daratumumab and 
in daratumumab-treated patient samples. The DIRA 
limit of sensitivity was 0.2 g/L daratumumab, using 
spiking  experiments. Results from DIRA were repro-
ducible over multiple days, operators, and assays. The 
anti- daratumumab antibody was highly specific for 
 daratumumab and did not shift endogenous M-protein.
Conclusions: As the treatment of myeloma evolves to 
incorporate novel monoclonal antibodies, additional 
solutions will be needed for clinical monitoring of patient 
responses to therapeutic regimens. In the interim, assays 
such as DIRA can inform clinical outcomes by distinguish-
ing daratumumab from endogenous M-protein by IFE.
Keywords: complete response; daratumumab; immuno-
fixation electrophoresis; monoclonal antibody; multiple 
myeloma.
Introduction
Multiple myeloma (MM) is an incurable disease character-
ized by the presence of malignant plasma cells that secrete 
high levels of a monoclonal immunoglobulin protein 
(M-protein) [1, 2]. The International Myeloma Working 
Group (IMWG) has established criteria for clinical response 
 ©2016, A. Kate Sasser et al., published by De Gruyter.  
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to treatment in MM, which include changes in serum/urine 
M-protein levels by serum protein electrophoresis (SPE) 
and immunofixation electrophoresis (IFE), percentage of 
bone marrow plasma cells, and free light chain (FLC) ratios 
[3–5]. For a patient to be classified as having a complete 
response (CR) by IMWG criteria, the serum and urine must 
be negative for M-protein, as determined by IFE and SPE, 
and bone marrow plasma cells must be   ≤  5%. In serum 
FLC-only patients, CR is defined as a normal FLC ratio 
in addition to the other criteria required to classify a CR 
[4]. For the more robust, deeper classification of stringent 
complete response (sCR), all of the criteria for CR must be 
met, along with a normal FLC ratio and absence of clonal 
plasma cells in the bone marrow, as measured by 2- to 
4-color flow cytometry or immunohistochemistry.
The treatment of MM is evolving with the introduc-
tion of therapeutic monoclonal antibodies (mAbs) [6–8]. 
Since SPE and IFE are used to quantify and characterize 
the clonal nature of immunoglobulins, respectively, these 
assays are subject to interference from therapeutic mAbs 
[9, 10]. Experiments with spiked samples demonstrated 
that all mAbs evaluated could be detected by SPE and 
IFE, down to 0.1 g/L [10]. Interference on serum IFE from 
treated patients has been reported with several mAbs, 
including siltuximab, ofatumumab, and daratumumab [1, 
9, 10], and similar interference has been observed with elo-
tuzumab [7, 11]. The IMWG criteria for achieving CR specify 
no detectable M-protein by IFE and SPE [3]; thus, antibody 
interference can have a clinically important impact on the 
assessment of response to treatment and may result in 
underestimation of CR rates for mAb therapies. As thera-
peutic mAbs become utilized in myeloma, methods are 
needed to assess clinical responses, particularly CR/sCR, 
in light of this potential interference.
Daratumumab, a human IgG1κ mAb, binds with 
high affinity to a unique CD38 epitope, inducing tumor 
cell death through a variety of mechanisms, including 
complement-dependent cytotoxicity, antibody-dependent 
cell-mediated cytotoxicity, antibody-dependent cellular 
phagocytosis, and induction of apoptosis [12–15]. Addi-
tionally, subpopulations of regulatory T cells, regulatory 
B cells, and myeloid-derived suppressor cells with high 
CD38 expression are sensitive to daratumumab [16]. Cyto-
toxic T cell activation, expansion, and increased T cell 
clonality have been observed after monotherapy treat-
ment in relapsed or refractory disease, suggesting a possi-
ble immunomodulatory role for daratumumab in MM [16].
In GEN501, a phase 1/2 study of patients with relapsed 
or refractory MM, daratumumab monotherapy was well 
tolerated, and 36% of patients receiving daratumumab at 
16 mg/kg achieved at least a partial response (PR) or better 
[6]. SIRIUS, a phase 2 study, examined daratumumab in 
patients with at least three lines of prior therapy or double 
refractory MM [8]. Overall response rate (ORR) was 29% and 
responses deepened with continued treatment; median 
overall survival was 17.5 months (95% confidence interval, 
13.7–not estimable) in these heavily pretreated patients 
(median of 5 prior lines of treatment) [8]. On the basis of 
these studies, daratumumab was recently approved in the 
United States for the treatment of patients with MM who 
have received 3 or more lines of prior therapy including 
a proteasome inhibitor (PI) and immunomodulatory drug 
(IMiD), or are double refractory to a PI and an IMiD [17]. 
Daratumumab is also being investigated in phase 3 clini-
cal studies in combination with other therapeutic agents 
in patients with MM.
At the recommended dosing schedule (16 mg/kg 
weekly for 8 weeks, then every 2 weeks for 16 weeks, 
and every 4 weeks thereafter), daratumumab reaches 
peak serum concentrations of approximately 915 μg/mL 
(0.915  g/L) at the end of the weekly dosing period [18], 
making it readily detectable on most SPE/IFE assays [1]. 
As a human IgGκ immunoglobulin, daratumumab may 
be detected by IFE and can thus be misinterpreted as a 
myeloma-associated M-protein, thereby interfering with 
the response criteria [19].
To help distinguish daratumumab from endogenous 
M-protein in serum IFE, the daratumumab-specific immu-
nofixation electrophoresis reflex assay (DIRA) was devel-
oped to confirm suspected daratumumab interference and 
to allow separation of daratumumab bands from residual 
endogenous M-protein. DIRA relies on the use of an anti-
daratumumab antibody that binds daratumumab and 
alters its migration on IFE. The present study describes the 
validation of DIRA for clinical trial testing, which included 
determination of the assay’s limit of sensitivity, specific-
ity, and reproducibility. This assay is currently being uti-
lized in clinical trials to distinguish daratumumab from 
endogenous M-protein by IFE and has triggered additional 
clinical response assessments to confirm CRs in myeloma 
patients treated with daratumumab.
Materials and methods
Serum sample collection
Human serum samples from patients with MM or healthy donors 
were acquired from a commercial source (Bioreclamation, Westbury, 
NY, USA) or from daratumumab-treated patients (n = 33). Serum sam-
ples from clinical trials of daratumumab as monotherapy (GEN501 
and SIRIUS) or as combination therapy with lenalidomide in an 
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ongoing study (GEN503; ClinicalTrials.gov Identifier: NCT01615029) 
were collected in 2.5 or 8.5  mL serum separator tubes (Becton 
 Dickinson, Franklin Lakes, NJ, USA) and centrifuged at 1300–2000 × g 
for 10–15 min, after 30 min at room temperature, to allow complete 
blood clotting/cooling. Serum samples were collected and shipped 
(frozen) to a central laboratory (BARC, Ghent, Belgium) for SPE and 
IFE or subsequent DIRA testing. Patients with low-level ( < 5 g/L) or 
negative SPE but repeated positive IgGκ IFE were flagged as having 
potential daratumumab interference, and were utilized for valida-
tion and DIRA testing. Samples were based on suspected interference 
rather than predefined time points. Clinical trials were approved by 
the independent Institutional Review Boards at study sites in accord-
ance with the Declaration of Helsinki and consistent with Good Clini-
cal Practices. All patients provided written informed consent.
Anti-daratumumab antibody
A murine anti-daratumumab antibody clone (5–3–9–4) (John-
son  & Johnson, New Brunswick, NJ, USA) was produced from a 
hybridoma cell line (Genmab, Utrecht, The Netherlands). Superna-
tants from cultured cells were concentrated using tangential flow 
filtration ( Millipore, Billerica, MA, USA), purified by MabSelect-
Sure (GE  Healthcare, Marlborough, MA, USA), and dialyzed into 
 Dulbecco’s phosphate-buffered saline, pH  7.2 (Life Technologies, 
Grand Island, NY, USA).
IFE and SPE
Immunofixations were performed on semi-automatic Hydrasys or 
Hydrasys 2 using Maxikit Hydragel 4IF or 9IF (Sebia, Norcross, GA, 
USA). SPE was performed on Capillarys using the Capillarys Protein 6 
kit (both from Sebia). Both IFE and SPE were performed according to 
the manufacturer’s specifications.
DIRA
For DIRA, anti-daratumumab or saline was spiked into baseline or 
daratumumab-treated patient serum, incubated at room temperature 
for 15 min, and separated by electrophoresis according to the stand-
ard IFE methods described previously. One lane of each baseline and 
daratumumab-treated patient serum was fixed as a reference and anti-
human, anti IgG, or κ (Sebia) antisera were applied to detect heavy and 
light chains. Upon completion of electrophoresis and staining, gels 
were assessed for (1) migration of control daratumumab with anti-dara-
tumumab, (2) lack of migration of baseline M-protein with the addi-
tion of anti-daratumumab, (3) a shift in the migration pattern of the 
putative daratumumab band relative to the daratumumab control in 
daratumumab-treated serum samples, and (4) the presence or absence 
of a non-daratumumab M-protein band. The absence of remaining dis-
ease M-protein was defined as a DIRA-negative result. The presence of 
remaining disease M-protein qualified as a DIRA-positive result.
Limit of sensitivity
Ten commercial MM samples were spiked with 0.25, 0.5, and 1.0 g/L 
daratumumab with and without anti-daratumumab in a 1:1 ratio to 
determine the effectiveness and reproducibility of anti-daratumumab 
to shift daratumumab bands. Ten additional MM serum samples and 
10 normal human serum (NHS) samples were spiked with a wider 
range of clinically relevant concentrations of daratumumab (0, 0.1, 
0.2, 0.25, and 0.5 g/L) with and without anti-daratumumab in a 1:1 
ratio. Two independent reviewers evaluated the results.
The limit of sensitivity was defined as the lowest level of dara-
tumumab detectable by at least one parameter (daratumumab IgG, 
daratumumab + anti-daratumumab complex IgG, daratumumab κ, 
or daratumumab + anti-daratumumab κ by IFE; daratumumab or 
daratumumab + anti-daratumumab by SPE) in all samples tested.
Specificity
To demonstrate that the anti-daratumumab antibody did not shift 
endogenous M-protein migration, commercially available serum sam-
ples from patients with MM (n = 51) were spiked with daratumumab, 
anti-daratumumab, or daratumumab + anti-daratumumab (0.5 g/L 
and 1 g/L; 1:1 ratio) and were analyzed by IFE. Additionally, a subset 
(n = 35) evaluated fixed concentrations of 1 g/L anti-daratumumab 
and 0.5 g/L daratumumab. Gels were assessed by determining 
whether there was a shift in daratumumab, with no corresponding 
shift in M-protein with anti-daratumumab alone. In addition, in each 
DIRA assay, control serum samples from patients prior to treatment 
with daratumumab were spiked with anti-daratumumab and evalu-
ated for a shift of endogenous M-protein on IFE.
Reproducibility
Three independent runs of 10 commercial samples spiked with 0.25, 
0.5, and 1 g/L daratumumab and 10 samples from daratumumab-
treated patients with M-protein   ≤  5 g/L, by SPE, were performed 
using DIRA. The results were assessed for reproducibility by two 
independent reviewers. The reviewers’ evaluations were standard-
ized using predefined assessment criteria. These criteria, as well as 
the reviewers’ responses to a single sample, are shown in Table  1. 
Inter-day and inter-operator reproducibility was evaluated using 
three commercial MM samples on three separate days by two opera-
tors, and interpreted by two independent reviewers.
Results
Daratumumab can be shifted with 
anti-daratumumab
To determine whether a shift in daratumumab could be 
detected by SPE and IFE, spiking experiments were per-
formed, with varying concentrations of daratumumab with 
or without anti-daratumumab added to myeloma serum 
or NHS and analyzed by SPE or IFE. Daratumumab was 
effectively detected and shifted with anti-daratumumab 
in all samples tested. (Figure  1A and data not shown). 
To evaluate the amount of anti-daratumumab needed to 
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Figure 1: Daratumumab can be identified on IFE/SPE and can be shifted with anti-daratumumab.
Daratumumab can be detected by IFE (A), anti-daratumumab antibody can bind and shift daratumumab migration pattern on IFE (B); 
1:1 ratios of daratumumab:anti-daratumumab are enough to completely shift daratumumab on IFE. Similarly, on SPE, a 1:1 ratio of 
daratumumab:anti-daratumumab was able to completely shift daratumumab (C). Daratumumab and daratumumab:anti-daratumumab 
complex are indicated by the blue and green arrows, respectively. IFE, immunofixation electrophoresis; SPE, serum protein electrophoresis; 
Dara, daratumumab.
Table 1: Concordance of reviewer assessments of the same sample across multiple experiments based on predefined acceptance criteria.
  Lane   Run 1   Run 2   Run 3
Reviewer 1        
  Migration of Dara + anti-Dara in control?   4 vs. 3   Y   Y   Y
  Migration of endogenous M-protein at baseline?   6 and 10   N   N   N
  Migration of Dara in  ≥ PR due to the disappearance of Dara (DD) 
or the appearance of Dara + anti-Dara complex (AC)?
  8 vs. 7 and 12 vs. 11  Y
DD+AC
  Y
DD+AC
  Y
DD+AC
  Presence of M-protein after migration of Dara?   8 and 12   N   N   N
  M-protein (M) or Dara (D)?     D   D   D
  Conclusion     Negative   Negative   Negative
Reviewer 2        
  Migration of Dara + anti-Dara in control?   4 vs. 3   Y   Y   Y
  Migration of endogenous M-protein at baseline?   6 and 10   N   N   N
  Migration of Dara in  ≥ PR due to the disappearance of Dara (DD) 
or the appearance of Dara + anti-Dara complex (AC)?
  8 vs. 7 and 12 vs. 11  Y
DD+AC
  Y
DD+AC
  Y
DD+AC
  Presence of M-protein after migration of Dara?   8 and 12   N   N   N
  M-protein (M) or Dara (D)?     D   D   D
  Conclusion     Negative   Negative   Negative
Dara, daratumumab; Y, yes; N, no; PR, partial response.
completely shift daratumumab on IFE and SPE, varying 
ratios of anti-daratumumab were spiked into serum con-
taining 1 g/L daratumumab, the maximum predicted 
concentration in patient serum after weekly dosing [15]. 
A 1:1 ratio of daratumumab:anti-daratumumab or excess 
anti-daratumumab completely shifted daratumumab on 
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IFE (Figure 1B). Excess mouse anti-daratumumab was not 
detected by human antiserum. Densitometry of SPE lanes 
showed a 1:1 ratio of daratumumab:anti-daratumumab 
was necessary to completely shift daratumumab; excess 
daratumumab or anti-daratumumab were also visualized 
as protein peaks since SPE does not discern total protein 
from human or mouse antibodies (Figure 1C). Because of 
its specificity for human antibody and its greater sensitiv-
ity, IFE was used to develop DIRA.
DIRA distinguishes daratumumab 
from endogenous M-protein
Among patients enrolled in daratumumab clinical 
studies, a residual IgGκ band or a faint IgGκ band that 
appeared over time was often observed on IFE. Daratu-
mumab interference was suspected and had the potential 
to mask CRs. DIRA was developed to distinguish daratu-
mumab from endogenous M-protein in patients with low 
measurable M-protein by SPE (  ≤  5 g/L) and IgGκ band by 
IFE. Exploratory analyses utilized samples with a higher 
range of SPE to help refine criteria for implementation 
and validation of the assay. Figure 2 shows a schematic 
that outlines the samples, controls, and loading in a 
typical DIRA.
DIRA evaluates patient samples prior to (baseline) and 
after treatment when daratumumab interference is sus-
pected. DIRA requires 12 sample lanes and uses a protein 
fixative and 2 antisera (IgG and κ; Figure 2A). Lanes 1 and 
2 comprise baseline and post-treatment samples with total 
protein fixative and display the migration patterns of all 
serum proteins at baseline and post-treatment. Lanes 3 
and 4 are controls containing daratumumab and dara-
tumumab + anti-daratumumab in saline, respectively. 
Lanes 5 and 6 (with anti-IgG antisera) include the base-
line sample alone and with anti-daratumumab, respec-
tively, to characterize endogenous M-protein migration 
and to demonstrate that anti-daratumumab alone has 
no effect on endogenous M-protein. Lanes 7 and 8 (with 
anti-IgG antisera) include the post-treatment sample 
alone and with anti-daratumumab, respectively, to char-
acterize daratumumab and to determine whether disease 
 M-protein remains. If the entire remaining band shifts with 
the addition of anti-daratumumab, indicating that endog-
enous M-protein is absent and that only daratumumab 
remains, the result is determined to be DIRA negative 
(similar to a standard IFE-negative result; Figure 2B). If 
the band only shifts partially, indicating that endogenous 
M-protein remains, the result is determined to be DIRA 
positive (similar to a typical IFE-positive result; Figure 2B). 
Lanes 9 through 12 contain the same samples as lanes 5 
through 8, but are probed with anti-κ antisera.
Validation of DIRA
For clinical validation, the sensitivity, specificity, and 
reproducibility of DIRA, in both commercial and daratu-
mumab-treated myeloma serum samples, were evaluated. 
Sensitivity was determined by evaluating 10 myeloma and 
10 NHS samples spiked with a range of daratumumab ± 
anti-daratumumab by SPE and IFE. Due to the potential for 
daratumumab or the daratumumab-anti- daratumumab 
complex to comigrate with M-protein with either IgG or κ 
antisera, sensitivity was defined by detection by at least 
one parameter (daratumumab or daratumumab + anti-
daratumumab complex with IgG or κ by IFE; daratumumab 
or daratumumab + anti-daratumumab complex by SPE). 
The sensitivity per sample was defined by the lowest level 
of daratumumab that could be detected by any of these 
parameters. In myeloma serum samples, the sensitivity of 
DIRA was determined to be 90% for 0.1 g/L daratumumab 
and 100% for 0.2 g/L by IFE. In NHS, the sensitivity of 
DIRA by IFE was 80% for 0.1 g/L daratumumab and 100% 
for 0.2 g/L. By SPE, sensitivity was determined to be 30% 
for 0.1 g/L and 100% for 0.2 g/L in MM serum and 100% at 
0.2 g/L in NHS. Therefore, the sensitivity of DIRA for dara-
tumumab is ~0.2 g/L. Typically MM patients are immuno-
suppressed, such that background polyclonal interference 
has not been an issue to date. In spiked NHS samples, it 
was not possible to consistently identify residual daratu-
mumab below 0.2 g/L. While IFE and thus DIRA is not a 
quantitative assay, determining the lower range of sensi-
tivity demonstrated daratumumab can be detected and 
DIRA is functional within the range of predicted serum 
concentrations in treated patients.
The specificity of DIRA relies on the specificity of the 
anti-daratumumab. Accordingly, DIRA includes control 
lanes containing baseline serum samples that have been 
spiked with or without anti-daratumumab (Figure  2, 
Lanes 5 and 6). In commercial samples spiked with 0.5 
or 1 g/L daratumumab, the antibody was shifted by anti- 
daratumumab at both concentrations in all samples (51 of 
51 [100%]). No shift in M-protein occurred with the addi-
tion of anti-daratumumab alone in any of the samples. 
When only anti-daratumumab was spiked into the serum, 
a weak polyclonal smear appeared in the lanes with IgG 
antisera in four of 51 (8%) samples. However, this did not 
interfere with the interpretation of DIRA, as the band cor-
responding to daratumumab:anti-daratumumab complex 
was distinctly visible and the smear was not observed 
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when daratumumab was present. While  experienced 
reviewers consistently identify the faint residual band in 
the DIRA assays, it may be difficult to identify in Figure 2B. 
This is a known issue with faint bands on agarose gels; 
scanned gels do not have the same resolution or detail as 
the physical version [20]. Therefore, anti- daratumumab 
appears highly specific for daratumumab. Specificity of 
the anti-daratumumab antibody, along with false-negative 
Figure 2: Daratumumab-specific IFE reflex assay.
Baseline (prior to treatment) serum samples are run ± anti-daratumumab next to serum samples from a post-treatment time point with 
suspected daratumumab interference, ± anti-daratumumab, to determine whether the remaining M-protein band shifts completely with anti-
daratumumab. Both IgG and κ antisera are used for staining and fixation (A). DIRA positive, similar to IFE positive, indicates that endogenous 
M-protein (in red, and indicated by a red arrow in lane 1) remains. DIRA negative, similar to IFE negative, indicates that only daratumumab (in 
blue, and indicated by a blue arrow in lane 3) is remaining and endogenous M-protein is no longer detected (A). The DIRA template utilized 
daratumumab ± anti-daratumumab as controls for migration of the therapeutic antibody and the daratumumab-anti- daratumumab shifted 
complexes (in green, and indicated by a green arrow in lane 4). In patient samples, baseline and post-treatment serum ± anti-daratumumab 
were compared to determine whether M-protein remained after shifting daratumumab (B). DIRA-positive results showed M-protein, whereas 
DIRA-negative results showed only a shift in daratumumab but no remaining M-protein (lanes 8 and 12). IFE, immunofixation electrophoresis; 
M-protein, monoclonal immunoglobulin protein; DIRA, daratumumab-specific immunofixation electrophoresis reflex assay; Dara, 
 daratumumab; PBS, phosphate buffered saline; SP, total serum protein fix; G, IgG antisera; κ, kappa antisera.
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and false-positive rates of DIRA, will be evaluated further 
in a randomized, phase 3 clinical study of daratumumab 
versus control.
The reproducibility of DIRA was assessed by perform-
ing the assay on daratumumab-treated patient samples 
in triplicate. In all daratumumab-treated patient samples 
(10/10), results were consistent across three independ-
ent experiments. To determine inter-operator and inter-
day reproducibility, DIRA was performed on commercial 
samples spiked with daratumumab ± anti-daratumumab, 
by two operators on three separate days. Further, results 
were evaluated by two independent reviewers. Concord-
ance among reviews was demonstrated in 100% of assays. 
Reviewers’ responses to a set of predetermined assess-
ment criteria are shown for a single patient sample over 
three separate experiments (Table 1).
DIRA Plus
To ensure 1 g/L anti-daratumumab was sufficient to shift 
daratumumab in patient serum samples for which dara-
tumumab concentration data were not available or SPE 
measurements were higher than the average range of 
daratumumab concentrations, samples from 14 dara-
tumumab-treated patients were tested using increased 
concentrations of anti-daratumumab (a modification 
known as “DIRA Plus”; Figure  3). For these assays, 
Figure 3: DIRA Plus for the evaluation of patients with serum con-
centrations of daratumumab above the normal range.
One gram per liter of anti-daratumumab was sufficient to migrate 
daratumumab in all samples (A). Higher concentrations of 
anti- daratumumab added to baseline serum (1 g/L and 4 g/L) 
resulted in the appearance of a faint, polyclonal smear (arrow) 
with IgG antisera. DIRA, daratumumab-specific immunofixation 
electrophoresis reflex assay; Dara, daratumumab; SP, total serum 
protein fix; G, IgG antisera; κ, kappa antisera.
anti-daratumumab concentrations of 1–4 g/L were used. 
In all cases (14 of 14 samples), 1 g/L of anti-daratumumab 
was sufficient to interpret DIRA. Anti-daratumumab con-
centrations of  ≥ 1 g/L caused a weak, polyclonal smear to 
appear with no other change in the assay result versus the 
standard concentration of 1 g/L. Thus, the use of concen-
trations of anti-daratumumab  > 1 g/L is neither warranted 
nor recommended.
Incorporation of DIRA into clinical testing
To automate the initiation of DIRA testing,  especially 
for phase 3 clinical trials with large numbers of daratu-
mumab-treated patients, an operational “ algorithm” for 
triggering DIRA was devised. The algorithm stipulates 
that, if only IgGκ M-protein is detected on IFE and urine 
and FLC results are normal, then DIRA testing should 
be performed for patients demonstrating M-protein 
levels   ≤  2 g/L by SPE on 2 consecutive visits (Figure 4). If 
the results are DIRA negative, patients will have additional 
testing to confirm CR, including bone marrow evaluation 
of plasma cells. If the results are DIRA positive, indicating 
≤2 g/L IgGκ
M-protein on 2
consecutive visits
No additional
M-proteins
detected
Urine and FLC
normal
Perform DIRA
Additional testing
to confirm CR
Continue to treat
and monitor
patient 
DIRA negative:
daratumumab
only
DIRA positive:
M-protein remains
Figure 4: Testing algorithm to implement DIRA for clinical response 
assessment.
Samples from a patient with   ≤  2 g/L IgGκ M-protein on two con-
secutive visits, with normal urine and FLC and without additional 
 M-protein, are good candidates for DIRA. For patients with DIRA-
negative samples, additional testing to confirm a putative CR is 
warranted. DIRA, daratumumab-specific immunofixation electropho-
resis reflex assay; M-protein, monoclonal immunoglobulin protein; 
FLC, free light chain; CR, complete response.
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remaining disease M-protein, then no additional testing 
is warranted and disease monitoring will be continued 
(Figure 4).
Discussion
Daratumumab, a human anti-CD38 mAb, has demon-
strated robust clinical efficacy in relapsed and refractory 
myeloma, including CRs in some patients. However, as a 
monoclonal immunoglobulin, daratumumab is detect-
able on the SPE and IFE assays that are used to monitor 
and characterize endogenous immunoglobulin protein. 
At the recommended 16 mg/kg dose and schedule, the 
mean (±standard deviation) maximum trough daratu-
mumab concentrations was 0.573±0.331 g/L, a concen-
tration which can interfere with interpretation of the SPE 
and IFE assays (data on file). Current IMWG criteria for a 
CR include negative serum and urine protein electropho-
resis and IFE, which is not possible when daratumumab 
is present at concentrations that fall within the therapeu-
tic range. Therefore, DIRA was developed, validated, and 
implemented to distinguish daratumumab from myeloma 
M-protein.
DIRA utilizes a highly specific anti-daratumumab 
antibody to bind daratumumab and shift its migration on 
IFE gels. Patients with a single IgGκ band that is shifted 
completely by DIRA are considered to have no remaining 
M-protein (DIRA negative) and, thus, are candidates for 
additional IMWG-required confirmatory testing, including 
bone marrow assessment for plasma cells, to determine 
whether criteria for CR/sCR (as defined by the IMWG) 
are met. Patients with remaining endogenous M-protein 
on DIRA are considered to be DIRA positive, and disease 
monitoring is continued.
DIRA was highly specific, sensitive, and reproducible 
both in commercial samples spiked with daratumumab and 
in clinical samples from daratumumab-treated patients. 
The presence, or even excess, of anti- daratumumab 
did not affect the detection or migration of endogenous 
M-proteins. In the absence of daratumumab, a weak poly-
clonal smear was observed in IgG antisera lanes in four of 
51 samples when anti-daratumumab was added, but the 
daratumumab:anti-daratumumab complex was still easily 
distinguishable by visual inspection and it did not inter-
fere with the interpretation of DIRA. DIRA was always able 
to detect daratumumab by at least one parameter. The limit 
of sensitivity of DIRA was determined to be 0.2 g/L in serum 
from patients with myeloma. At this concentration and 
above, daratumumab interference with  M-protein is pre-
dicted. Trough daratumumab concentrations throughout 
the weekly and every 2 weeks dosing periods are typically 
above the DIRA sensitivity and may result in daratumumab 
detection by IFE. However, daratumumab trough concen-
trations during every 4 weeks dosing may fall below the 
DIRA sensitivity and may not interfere with M-protein 
monitoring during this time. Further, DIRA could be 
modified for patients with higher than average serum con-
centrations (DIRA Plus) by increasing the amount of anti-
daratumumab used, although assay reliability decreased 
with increasing anti-daratumumab concentrations  > 1 g/L.
Reproducibility was assessed several different ways. 
Two independent reviewers scored all DIRA tests, and their 
assessments were always in agreement; a third reviewer 
was never required. Reproducibility tests were performed 
with 10 samples, and results for individual samples were 
consistent across multiple repetitions; similar results were 
obtained. Taken together, these findings indicate that 
DIRA is a robust test with high sensitivity, specificity, and 
reproducibility.
Despite these advantages, DIRA also has limitations. 
First, DIRA is not quantitative and interpretation by a 
trained operator is required. Although rare in myeloma, 
high polyclonal background signals may make it diffi-
cult to assess responses in some patients, leading to false 
interpretations. Second, DIRA is highly specific to daratu-
mumab. Responses in patients receiving other antibodies 
cannot be resolved using DIRA. Other potential methods 
to address antibody interference, such as mass spectrom-
etry, will be needed for patients receiving combinations of 
antibodies or patients requiring quantitative testing.
DIRA is important for determining response in dara-
tumumab clinical studies, particularly for patients with 
IgGκ M-protein. Patients with non-IgGκ endogenous 
serum M-proteins (i.e. urine, FLC, IgA κ or λ, or IgGλ 
M-proteins) that were positive for IgGκ by IFE were readily 
detected using DIRA but, to meet current IMWG criteria, 
they also had to be evaluated to demonstrate that only 
daratumumab remained.
In phase 2 studies, an IgGκ band often appeared in 
SPE/IFE over the course of daratumumab treatment in 
patients originally classified as having non-IgGκ myeloma 
(IgA, IgM, IgE myeloma, or light-chain–only myeloma). 
It is likely that this band is indicative of daratumumab 
interference rather than a new plasma cell clone secreting 
an IgG monoclonal M-protein. In cases where the origi-
nal myeloma clone was IgA or light chain only, reported 
as approximately 24% and 11% of patients in the general 
myeloma population, respectively [21], daratumumab 
was easily identified with DIRA and a lack of endogenous 
M-protein could be confirmed. However, 60% of patients 
with MM have IgG M-protein [21], and for those with IgGκ 
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the distinction between daratumumab and endogenous 
M-protein can be difficult. The most difficult cases to inter-
pret were those in which the migration of daratumumab 
completely overlapped with M-protein and the entire 
band did not shift with anti-daratumumab. Waiting until 
M-protein measurements on SPE were lower, in accord-
ance with the operational algorithm, reduced the number 
of these cases. IMWG has recently released a clarification 
to address antibody interference. In these updated guide-
lines, only the original myeloma clone(s) are required to 
be undetectable by SPE/IFE [22]. However, DIRA can still 
distinguish IgGκ clones from daratumumab.
The development and validation of DIRA offers a 
solution to mitigate daratumumab interference in IFE and 
improve clinical response assessment in daratumumab-
treated patients. Until recently, the modest success of 
mAbs for the treatment of MM in the clinic did not neces-
sitate a solution for mAb assay interference. Phase 1 and 
2 studies of daratumumab as a monotherapy have yielded 
deep responses, including CRs and sCRs [6, 8], making it 
essential to establish a reliable method for distinguish-
ing M-protein from daratumumab. As myeloma therapy 
evolves to incorporate additional mAb therapeutics, other 
methods to mitigate antibody interference on SPE/IFE will 
be needed. These alternative methods could include the 
incorporation of minimal residual disease (MRD) detec-
tion into formal clinical criteria for CR and sCR. MRD 
detection by 8- to 10-color flow cytometry could be sus-
ceptible to antibody interference as well, but standardized 
approaches using noncompeting antibodies may offer 
a solution. Utilization of methods such as polymerase 
chain reaction/next-generation sequencing could also be 
evaluated.
Conclusions
DIRA is an effective test with high sensitivity, specificity, 
and reproducibility to distinguish endogenous M-pro-
tein from daratumumab. DIRA is currently employed 
in daratumumab clinical trials to determine if patients 
with outcomes of very good PR should undergo con-
firmatory assessments for characterization of CR. These 
studies will provide functional validation of DIRA as a 
clinical tool.
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